Updates on the pathophysiology and treatment of aplastic anemia: a comprehensive review
- 24 April 2017
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 10 (5) , 433-448
Abstract
Introduction: The past decade or longer has witnessed an acceleration in our understanding of previously developed immune system and clonal evolution mechanisms, and the genesis of more novel concepts of telomere attrition. Many of these concepts are steadily finding their way into translation in various aspects of clinical practice, and provide prospects to improve AA management and inform therapeutic strategy development. In this review, we intend to discuss the pathophysiology and treatments with an emphasis on most recent developments to provide an update on our understanding of disease mechanisms. Areas covered: A literature search was undertaken addressing various aspects of pathophysiology with a focus on the role of immune system repertoire, telomeres and mutational events surrounding AA. We also reviewed upon the temporal evolution of treatment strategies in AA to the contemporary management of today and commented briefly upon the more recently investigated novel therapies and their expanding niche especially in the transplant and salvage setting. Expert commentary: Immune-mediated destruction of hematopoietic stem and progenitor cells, leading to a marrow devoid of hematopoietic elements, and peripheral pancytopenia are the hallmarks of AA. Recent studies have shed light on another facet of the disease – as a clonal disorder characterized by karyotypic abnormalities, genomic instability, telomere attrition, and recurrent somatic mutations reminiscent of myeloid malignancies. Further understanding of this underlying pathophysiology can help in improving prognostication and treatment of this disease.Keywords
Funding Information
- National Cancer Institute (P30 CA016672)
This publication has 126 references indexed in Scilit:
- Eltrombopag and Improved Hematopoiesis in Refractory Aplastic AnemiaNew England Journal of Medicine, 2012
- Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemiaBlood, 2012
- The replication rate of human hematopoietic stem cells in vivoBlood, 2011
- Highly skewed T-cell receptor V-beta chain repertoire in the bone marrow is associated with response to immunosuppressive drug therapy in children with very severe aplastic anemiaBlood Cancer Journal, 2011
- Fanconi anemia and its diagnosisMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009
- HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation CyclophosphamideTransplantation and Cellular Therapy, 2008
- Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemiaBlood, 2007
- Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimensBlood, 2007
- Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapyBlood, 2006
- Treatment of Aplastic Anemia With an Investigational Antilymphocyte Serum Prepared in RabbitsThe American Journal of the Medical Sciences, 1994